Targets › ROTV
1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease.
Open in Phaseline: the race on ROTV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MAXVAX Biotechnology Limited Liability Company | Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose) Recombinant rotavirus subunit vaccine with P types; adjuvanted with aluminum hydroxide | ROTV | Phase 2 | Rotavirus Infections | – |
Rotavirus Infections (2)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.